Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback